Kailera
formerly Kailera TherapeuticsIPOElevating the Next Era of Obesity Care
Kailera was founded in 2024, is headquartered in Waltham, United States, lists 51–200 employees, and has $1.0B in recorded funding across 2 rounds.
- Headquarters
- Waltham, Massachusetts
- Employees
- 51–200
- Founded
- 2024
- Business Model
- B2B
- Website
- kailera.com
- Total Funding
- $1.0B
- Last Round
- $600.0M Series BOct 2025
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 5 investors for this company. The full record is or through the API.
About
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive, and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities, Kailera's vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. The company's lead product candidate, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently being evaluated in a global Phase 3 program.
Summary
Kailera is a Biotech company based in Waltham, United States, founded in 2024. It lists 51–200 employees. It has raised $1.0B in total across 2 rounds, most recently a $600.0M Series B round in Oct 2025. Investors include Bain Capital Private Equity, Atlas Venture and Bain Capital Life Sciences.
Tech & App Stack
7 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Jun 2026
Sign up to see all 3 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/kailera"><img src="https://indexed.vc/api/badge/company/kailera" alt="Kailera on Indexed.vc" width="260" height="76" /></a>